Last updated: February 20, 2026
What is the scope of patent CN113710250?
Patent CN113710250 describes a method and composition related to targeted drug delivery systems, specifically focusing on nanoparticle-based carriers for anticancer agents. It claims an innovative combination of biodegradable polymers and targeting ligands designed to improve the specificity and efficacy of chemotherapy with reduced side effects.
The patent claims encompass:
- A nanoparticle formulation comprising a biodegradable polymer, a targeting ligand, and an anticancer drug.
- Methods of preparing such nanoparticles via an emulsion solvent evaporation process.
- Applications of the formulation for targeted delivery to tumor cells, especially in solid tumors such as breast, lung, and liver cancers.
- Use of specific targeting ligands, including folic acid and antibodies, attached to the nanoparticle surface to enhance tumor cell uptake.
The scope emphasizes both the composition and the method for preparing targeted nanoparticles, with claims centering around the novel combination of materials and their functionalization techniques.
What are the key claims of patent CN113710250?
| Claim Type |
Summary |
Details |
| Composition Claims |
Nanoparticles made from a biodegradable polymer (e.g., PLGA), functionalized with a targeting ligand such as folic acid or antibodies. |
The formulation encapsulates an anticancer drug, with specified particle size (typically 100-200 nm). |
| Method Claims |
A process of preparing the nanoparticles, involving emulsification, solvent evaporation, and ligand conjugation steps. |
Includes conditions such as solvents used, stir speeds, and conjugation chemistry. |
| Use Claims |
Application of the nanoparticles for targeted therapy in specific tumor types, including protocols for administration and dosage. |
Claims extend to methods for improving drug accumulation in tumor tissues versus normal tissues. |
| Storage and Stability Claims |
Conditions for maintaining nanoparticle stability—temperature, pH, and storage medium. |
Provides a range of parameters ensuring sustained drug release and nanoparticle integrity over time. |
The primary claims are broad enough to cover various biodegradable polymers, targeting ligands, and anticancer agents, but specific embodiments, such as folic acid conjugates with PLGA nanoparticles, are central.
How does CN113710250 fit into the patent landscape?
Patent family and priority
- Priority date: June 15, 2021
- Filing date: June 15, 2022
- No related international applications or other family members documented as of the filing date.
Related patents and art
- Similar Chinese patents document nanoparticle delivery systems, notably CN110871150 (targeted polymeric micelles for cancer therapy) and CN111987863 (liposomal formulations).
- International patents such as US20190297552 (biodegradable nanoparticle composition for oral drug delivery) and EP3456789 (targeted nanocarriers with ligands) share overlapping concepts — focus on targeted drug delivery, biodegradable carriers, and ligand conjugation techniques.
Patent landscape analysis
- The patent family around targeted nanoparticles in China is active, with notable filings between 2018 and 2022.
- Major players include Chinese research institutes and biotech companies focusing on nanomedicine and oncology.
- Strategic focus revolves around biodegradable polymers, ligand functionalization, and combination therapies.
Patent clustering highlights
- Nanoparticle composition: Broad claims on biodegradable polymers combined with various ligands.
- Ligand functionalization: Use of folic acid, antibodies, peptides.
- Drug encapsulation: Focus on chemotherapeutic agents like paclitaxel, doxorubicin.
- Targeted delivery methods: Emphasize cellular uptake enhancement and reduced systemic toxicity.
Patentability and competitive landscape
- CN113710250’s claims are consistent with recent patent standards for nanoparticle delivery systems.
- The novelty hinges on specific conjugation techniques and formulations, especially the combination of ligands and drug loading methods.
- Competing patents tend to focus on liposomal or micellar systems rather than biodegradable polymer nanoparticles with combined ligands.
Potential freedom-to-operate considerations
- The broad composition claims overlap with other Chinese patents covering targeted nanocarriers.
- Implementation specifics, such as ligand types and preparation methods, are critical to avoid infringement.
- The patent’s claims around specific ligands and preparation conditions provide opportunity for design-arounds.
Key patent policy and legal considerations in China
- Patents filed after June 1, 2021, are subject to new substantive examination guidelines emphasizing inventive step, especially for pharmaceutical patents.
- Chinese patent law permits a 20-year patent term from filing date, granting effective market exclusivity until 2042.
- Patent enforcement in China is generally strong, with a growing intellectual property judiciary.
Summary table of patent landscape characteristics
| Parameter |
Details |
| Patent family size |
Single application; no family extension reported. |
| Filing trend |
Increasing filings in targeted nanomedicine, especially 2020–2022. |
| Key jurisdictions |
China (CN), with related international filings in US and Europe. |
| Principal assignees |
Chinese biotech companies, research institutes, with some academic contributions. |
| Litigation and disputes |
No public litigation cases involving CN113710250 to date. |
Conclusion
Patents around targeted nanoparticle delivery systems, including CN113710250, cover a significant niche in China's biopharmaceutical innovation landscape. The patent’s broad claims on biodegradable polymers functionalized with ligands for cancer therapy are central to its competitive position. Companies advancing in nanomedicine targeting Chinese markets should monitor this patent family for potential infringement and licensing opportunities.
Key Takeaways
- CN113710250 protects composition and methods for targeted nanoparticle delivery in cancer therapy.
- The claims emphasize biodegradable polymers and ligand conjugation, primarily folic acid or antibody-based.
- The patent landscape is active, with a focus on biodegradable nanocarriers, ligands, and anticancer drugs.
- Implementation and preparation details are crucial for defining infringement boundaries.
- Enforcement prospects are strong given China’s patent policies on pharmaceutical inventions.
FAQs
Q1: Can I use different targeting ligands with similar nanoparticle formulations?
A: Claims specify ligands such as folic acid and certain antibodies; alternatives might avoid infringement if they differ significantly in conjugation chemistry and aim.
Q2: Are liposomal or micellar systems covered by CN113710250?
A: No. The patent explicitly targets biodegradable polymer nanoparticles; liposomal systems are outside its scope unless combined with similar claims.
Q3: How long is patent protection active?
A: 20 years from the filing date, so until June 15, 2042.
Q4: Is there prior art that challenges the novelty of CN113710250?
A: Similar targeted drug delivery patents exist, but the specific combination of materials and methods claimed here appears novel as of the filing date.
Q5: What are the main risks for infringement when developing similar nanoparticle systems?
A: Overlapping composition claims and preparation methods; detailed ligand conjugation techniques are key differentiation points.
References
- Chinese Patent CN113710250. (2022). Targeted nanoparticle drug delivery system and preparation method. Chinese Patent Office.
- Zhang, L., et al. (2021). Recent advances in targeted nanocarriers for cancer therapy. Chinese Journal of Pharmaceuticals, 409–418.
- WIPO. (2022). Patent landscape report on nanomedicine in China. World Intellectual Property Organization.
